Ataxie Marktgröße, Anteil, Wachstum, Trends, Analyse, Prognose, Segmentierung, Forschungsbericht Bis 2029

Global Ataxia Market

Marktgröße in Milliarden USD

CAGR : 6.90 %

Prognosezeitraum	2022 –2029
Marktgröße (Basisjahr)	USD 22,631.81 Thousand
Marktgröße (Prognosejahr)	USD 36,900.18 Thousand
CAGR	6.90 %
Wichtige Marktteilnehmer	Novartis Merck Aurobindo Pharma Pfizer Sanofi

Globaler Ataxiemarkt nach Typ ( Spinozerebelläre Ataxien, Ataxia-Teleangiektasie, episodische Ataxie und andere (Multisystematrophie (MSA))), Produkt (Behandlung und Diagnose), Darreichungsform (fest, flüssig und andere), Verabreichungsweg (oral, parenteral und andere), Patiententyp (Erwachsene, Kinder und Geriatrie), Endbenutzer (Krankenhaus, Kliniken, häusliche Pflege und andere), Vertriebskanal (direkte Ausschreibung, Einzelhandelsverkauf und andere) – Branchentrends und Prognose bis 2029.

Ataxia-Markt

Globale Ataxie-Marktanalyse und Einblicke

Die zunehmende Verbreitung der Ataxie-Krankheit hat die Nachfrage auf dem Markt erhöht. Die steigenden Gesundheitsausgaben für bessere Gesundheitsdienste tragen ebenfalls zum Wachstum des Marktes bei. Während dieser entscheidenden Phase konzentrieren sich die wichtigsten Marktteilnehmer stark auf Produkteinführungen und Produktzulassungen. Darüber hinaus unterstützen Regierung und Aufsichtsbehörden die Marktteilnehmer aufgrund der steigenden Zahl an neuen Produkten durch Produktzulassungen.

Globaler Ataxiemarkt

Der globale Ataxiemarkt wächst im Prognosejahr aufgrund der Zunahme der Marktteilnehmer und der Verfügbarkeit fortschrittlicher Produkte. Darüber hinaus betreiben die Hersteller Forschungs- und Entwicklungsaktivitäten, um neue Produkte auf den Markt zu bringen. Die zunehmende Forschung auf dem Gebiet der Ataxietherapie und der Anstieg des Alkohol- und Drogenkonsums dürften das Marktwachstum weiter ankurbeln. Die Schwierigkeit bei der Diagnose der Krankheit und der Mangel an genetischen Testmöglichkeiten in einigen Entwicklungsländern könnten jedoch das Wachstum des globalen Ataxiemarktes im Prognosezeitraum behindern.

Die steigenden Gesundheitsausgaben und strategischen Initiativen der Marktteilnehmer könnten dem Markt Chancen eröffnen, die Behandlung zu verbessern. Allerdings dürften einige strenge Regeln und Vorschriften im Zusammenhang mit der Zulassung von Medikamenten und Produkten sowie Produktrückrufe verschiedener Unternehmen das Marktwachstum behindern.

Der globale Ataxiemarkt wird im Prognosezeitraum von 2022 bis 2029 voraussichtlich ein Marktwachstum verzeichnen. Data Bridge Market Research analysiert, dass der Markt im Prognosezeitraum von 2022 bis 2029 mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 6,9 % wächst und von 22.631,81 Tausend USD im Jahr 2021 auf 36.900,18 Tausend USD im Jahr 2029 ansteigen dürfte.

Berichtsmetrik	Details
Prognosezeitraum	2022 bis 2029
Basisjahr	2021
Historische Jahre	2020
Quantitative Einheiten	Umsatz in Tausend USD, Preise in USD
Abgedeckte Segmente	Nach Typ (Spinocerebelläre Ataxien, Ataxia-Teleangiektasie, episodische Ataxie und andere (Multisystematrophie (MSA))), Produkt (Behandlung und Diagnose), Darreichungsform (fest, flüssig und andere), Verabreichungsweg (oral, parenteral und andere), Patiententyp (Erwachsene, Kinder und Geriatrie), Endverbraucher (Krankenhaus, Klinik, häusliche Pflege und andere), Vertriebskanal (direkte Ausschreibung, Einzelhandelsverkauf und andere)
Abgedeckte Länder	USA, Kanada, Mexiko, Deutschland, Frankreich, Großbritannien, Italien, Spanien, Niederlande, Schweiz, Irland, Russland, Ungarn, Österreich, Norwegen, Polen, Türkei, Litauen, Restliches Europa, China, Japan, Indien, Südkorea, Australien, Singapur, Thailand, Malaysia, Indonesien, Philippinen, Vietnam, Restlicher Asien-Pazifik-Raum, Südafrika, Saudi-Arabien, Vereinigte Arabische Emirate, Ägypten, Israel, Kuwait, Restlicher Naher Osten und Afrika
Abgedeckte Marktteilnehmer	Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics, Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Amneal Pharmaceuticals LLC., Apotex Inc., Cipla Inc., Biovista, Design Therapeutics Inc., Reata Pharmaceuticals, Inc., MATRIX BIOMED, Intrabio, Biohaven Pharmaceuticals, Retrotope Inc., Adverum Biotechnologies, Inc., Priory., Sutter Health., Upstream Rehabilitation Inc., Banner Health, Select Medical Corporation, ATI Physical Therapy und andere

Marktdefinition

Ataxie ist ein Begriff für eine Gruppe von Störungen, die Koordination, Gleichgewicht und Sprache beeinträchtigen. Jeder Körperteil kann betroffen sein, aber Menschen mit Ataxie haben oft Probleme mit dem Gleichgewicht, Gehen, Sprechen, Schlucken und Aufgaben, die ein hohes Maß an Kontrolle erfordern, wie Schreiben, Essen und Sehen. Die genauen Symptome und ihre Schwere variieren je nach Art der Ataxie, an der eine Person leidet.

Ataxie ist in der Regel das Ergebnis einer Schädigung eines Teils des Gehirns, des Kleinhirns, kann aber auch durch eine Schädigung anderer Teile des Nervensystems verursacht werden. Diese Schädigung kann Teil einer Grunderkrankung wie MS (Multiple Sklerose) sein oder durch eine Kopfverletzung, Sauerstoffmangel im Gehirn oder langfristigen, übermäßigen Alkoholkonsum verursacht werden. Erbliche Ataxie wird durch ein fehlerhaftes Gen verursacht, das von Familienmitgliedern weitergegeben wird, die betroffen sein können, aber nicht müssen.

Globale Ataxie-Marktdynamik

Treiber

Zunehmende Prävalenz und Inzidenz von Ataxie

Ataxie ist der Begriff für eine Gruppe neurologischer Erkrankungen des Nervensystems, die Bewegung und Koordination beeinträchtigen. Menschen mit Ataxie haben häufig Probleme mit Gleichgewicht, Koordination, Schlucken und Sprechen. Ataxie entsteht normalerweise aufgrund einer Schädigung eines Teils des Gehirns, nämlich des Kleinhirns, das die Bewegung koordiniert. Es handelt sich um eine seltene Krankheit, die weltweit sehr häufig auftritt. Die Krankheit wird weltweit als großes klinisches Problem anerkannt, das eine hohe Morbiditäts- und Mortalitätslast mit sich bringt. Daher treiben die zunehmende Prävalenz und Inzidenzrate von Ataxie, die verschiedene Altersgruppen betrifft, den globalen Ataxiemarkt an.

Schnelle Forschung im Bereich der Ataxie-Therapeutika

Es gibt eine enorme Bandbreite an Risikofaktoren, die für Ataxie gemeldet werden. Um die damit verbundenen Risikofaktoren und Symptome zu reduzieren, werden daher verschiedene Forschungsarbeiten im Bereich der Ataxiebehandlung durchgeführt. Es wurden auch einige staatliche Mittel für die Behandlung verschiedener Arten von Ataxie auf dem Markt bereitgestellt. Verschiedene schnelle Forschungsarbeiten im Bereich der Ataxietherapie können dazu beitragen, den Markt im Prognosezeitraum anzukurbeln und ein starkes Wachstum in der Forschung und Entwicklung in diesem Bereich zu erwarten.

Anstieg des Alkohol- und Drogenkonsums

Steigender Alkohol- und Drogenkonsum kann zu Vitamin-B12-, Vitamin-E- und Thiaminmangel führen. Der Mangel an diesen Nährstoffen im Körper gilt als Hauptursache für Ataxie. Ein Mangel an Vitamin E im Körper kann zu neurologischen Problemen führen, wie z. B. Schwierigkeiten bei der Koordination von Bewegungen (Ataxie) und Sprache (Dysarthrie), Verlust der Reflexe in den Beinen (Areflexie der unteren Extremitäten) und Gefühlsverlust in den Extremitäten (periphere Neuropathie), was wiederum zu den verschiedenen Arten von Ataxie führt. Die steigende Zahl von Menschen und Jugendlichen, die übermäßig Alkohol und Drogen konsumieren, erhöht auch die Wahrscheinlichkeit, von verschiedenen Arten von Ataxie betroffen zu sein. Dies dürfte als Wachstumsmotor für den globalen Ataxiemarkt wirken.

Globaler Ataxiemarkt

Gelegenheiten

Steigende Gesundheitsausgaben

Die Gesundheitsausgaben sind weltweit gestiegen, da das verfügbare Einkommen der Menschen in vielen Ländern zunimmt. Um den Bedarf der Bevölkerung zu decken, ergreifen Regierungsbehörden und Gesundheitsorganisationen die Initiative, indem sie die Gesundheitsausgaben erhöhen. Der Anstieg der Gesundheitsausgaben hilft Gesundheitseinrichtungen gleichzeitig dabei, ihre Behandlungsmöglichkeiten für Ataxie zu verbessern, da die Krankheit in den letzten Jahren sehr verbreitet war.

Einschränkungen/Herausforderungen

Die Schwierigkeiten bei der Diagnose der Krankheit und der Mangel an genetischen Testmöglichkeiten in einigen Entwicklungsländern werden jedoch das Wachstum des globalen Ataxiemarktes hemmen. Darüber hinaus werden strenge Regeln und Vorschriften den Markt im Prognosezeitraum zusätzlich vor Herausforderungen stellen.

Dieser globale Ataxie-Marktbericht enthält Einzelheiten zu neuen Entwicklungen, Handelsvorschriften, Import-Export-Analysen, Produktionsanalysen, Wertschöpfungskettenoptimierungen, Marktanteilen, dem Einfluss inländischer und lokaler Marktteilnehmer, analysiert Chancen in Bezug auf neu entstehende Einnahmequellen, Änderungen der Marktvorschriften, strategische Marktwachstumsanalysen, Marktgröße, Kategoriemarktwachstum, Anwendungsnischen und -dominanz, Produktzulassungen, Produkteinführungen, geografische Expansionen und technologische Innovationen auf dem Markt. Um weitere Informationen zum globalen Ataxie-Markt zu erhalten, wenden Sie sich an Data Bridge Market Research, um einen Analyst Brief zu erhalten. Unser Team hilft Ihnen dabei, eine fundierte Marktentscheidung zu treffen, um Marktwachstum zu erzielen.

Auswirkungen von COVID-19 auf den globalen Ataxiemarkt

COVID-19 hat sich positiv auf den Markt ausgewirkt. Lockdowns und Isolation während einer Pandemie erschweren das Krankheitsmanagement und die Einhaltung von Medikamenten. Daher ist die Zahl der Medikamente zur Behandlung in der Weltbevölkerung stark gestiegen. Daher hat sich die Pandemie positiv auf diesen Markt ausgewirkt.

Jüngste Entwicklung

Im November 2022 gab Pfizer Inc. bekannt, dass das Unternehmen die Übernahme von Arena Pharmaceuticals abgeschlossen hat. Es handelt sich um ein Unternehmen in der klinischen Phase, das innovative potenzielle Therapien zur Behandlung mehrerer immun-entzündlicher Erkrankungen entwickelt. Dies hat dem Unternehmen geholfen, sein Produktportfolio mit dieser Übernahme zu erweitern

Globaler Ataxie-Marktumfang

Der globale Ataxiemarkt ist segmentiert nach Typ, Produkt, Darreichungsform, Verabreichungsweg, Patiententyp, Endverbraucher und Vertriebskanal. Das Wachstum dieser Segmente hilft Ihnen bei der Analyse schwacher Wachstumssegmente in den Branchen und bietet den Benutzern einen wertvollen Marktüberblick und Markteinblicke, um strategische Entscheidungen zur Identifizierung der wichtigsten Marktanwendungen zu treffen.

Typ

Spinozerebelläre Ataxien
Ataxie-Teleangiektasie
Episodische Ataxie
Andere (Multisystematrophie (MSA))

Auf der Grundlage des Typs ist der globale Ataxiemarkt in spinozerebelläre Ataxien, Ataxie-Teleangiektasie, episodische Ataxie und andere (Multisystematrophie (MSA)) segmentiert.

Produkt

Diagnose
Behandlung

Auf der Grundlage des Produkts ist der globale Ataxiemarkt in Behandlung und Diagnose segmentiert.

Darreichungsform

Solide
Flüssigkeiten
Sonstiges

Auf der Grundlage der Darreichungsform ist der globale Ataxiemarkt in fest, flüssig und sonstige Produkte segmentiert.

Verabreichungsweg

Oral
Parenterale
Sonstiges

Auf der Grundlage der Verabreichungsart ist der globale Ataxiemarkt in orale, parenterale und andere Verabreichungsarten segmentiert.

Patiententyp

Erwachsene
Kind
Geriatrie

Auf der Grundlage des Patiententyps ist der globale Ataxiemarkt in Erwachsene, Kinder und geriatrische Patienten segmentiert.

Endbenutzer

Krankenhaus
Kliniken
Häusliche Gesundheitspflege
Sonstiges

Auf der Grundlage der Endbenutzer ist der globale Ataxiemarkt in Krankenhäuser, Kliniken, häusliche Gesundheitspflege und Sonstiges segmentiert.

Vertriebskanal

Direkte Ausschreibung
Einzelhandelsumsätze
Sonstiges

Globaler Ataxiemarkt

Auf der Grundlage der Vertriebskanäle ist der globale Ataxiemarkt in Direktausschreibungen, Einzelhandelsverkäufe und Sonstiges segmentiert.

Globaler Ataxie-Markt – Regionale Analyse/Einblicke

Der globale Ataxiemarkt wird analysiert und es werden Einblicke in die Marktgröße und Trends nach Land, Typ, Produkt, Dosierungsform, Verabreichungsweg, Patiententyp, Endbenutzer und Vertriebskanal bereitgestellt, wie oben angegeben.

Zu den wichtigsten Ländern, die vom globalen Ataxiemarkt abgedeckt werden, zählen die USA, Kanada, Mexiko, Deutschland, Frankreich, Großbritannien, Italien, Spanien, die Niederlande, die Schweiz, Irland, Russland, Ungarn, Österreich, Norwegen, Polen, die Türkei, Litauen, das übrige Europa, China, Japan, Indien, Südkorea, Australien, Singapur, Thailand, Malaysia, Indonesien, die Philippinen, Vietnam, der übrige asiatisch-pazifische Raum, Südafrika, Saudi-Arabien, die Vereinigten Arabischen Emirate, Ägypten, Israel, Kuwait sowie der übrige Nahe Osten und Afrika.

Die USA, Deutschland und China werden voraussichtlich den Markt dominieren, da in diesen Regionen eine hohe Prävalenz von Ataxie in der Bevölkerung zu beobachten ist. Sie dominieren den globalen Ataxiemarkt in Bezug auf Marktanteil und Marktumsatz und werden ihre Dominanz im Prognosezeitraum weiter ausbauen. Dies ist auf steigende Gesundheitsausgaben zurückzuführen und die schnelle Forschungsentwicklung beflügelt den Markt.

Globaler Ataxiemarkt

Der Länderabschnitt des Berichts enthält auch Angaben zu einzelnen marktbeeinflussenden Faktoren und Änderungen der Marktvorschriften, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie Neu- und Ersatzverkäufe, demografische Daten des Landes, Krankheitsepidemiologie und Import- und Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Darüber hinaus werden bei der Prognoseanalyse der Länderdaten die Präsenz und Verfügbarkeit globaler Marken sowie ihre Herausforderungen aufgrund der hohen Konkurrenz durch lokale und inländische Marken und die Auswirkungen der Vertriebskanäle berücksichtigt.

Wettbewerbsumfeld und globale Ataxie- Marktanteilsanalyse

Die Wettbewerbslandschaft des globalen Ataxiemarktes liefert Einzelheiten zu den Wettbewerbern. Die enthaltenen Einzelheiten umfassen Unternehmensübersicht, Unternehmensfinanzen, erzielten Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, globale Präsenz, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen auf den globalen Ataxiemarkt.

Zu den wichtigsten Akteuren auf dem globalen Ataxiemarkt zählen unter anderem Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics, Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Amneal Pharmaceuticals LLC., Apotex Inc., Cipla Inc., Biovista, Design Therapeutics Inc., Reata Pharmaceuticals, Inc., MATRIX BIOMED, Intrabio, Biohaven Pharmaceuticals, Retrotope Inc., Adverum Biotechnologies, Inc., Priory., Sutter Health., Upstream Rehabilitation Inc., Banner Health, Select Medical Corporation und ATI Physical Therapy.

Forschungsmethodik

Die Datenerfassung und die Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Die wichtigste Forschungsmethode, die das DBMR-Forschungsteam verwendet, ist die Datentriangulation, die Data Mining, Analyse der Auswirkungen von Datenvariablen auf den Markt und primäre (Branchenexperten-)Validierung umfasst. Abgesehen davon umfassen die Datenmodelle ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, einen Marktüberblick und -leitfaden, ein Unternehmenspositionierungsraster, eine Unternehmensmarktanteilsanalyse, Messstandards, global vs. regional und eine Lieferantenanteilsanalyse. Bitte fordern Sie bei weiteren Fragen einen Analystenanruf an.

SKU-68179

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Klicken Sie auf das Bild, um es zu vergrößern

Interaktives Datenanalyse-Dashboard
Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
Zugriff für Research-Analysten für Anpassungen und Abfragen
Konkurrenzanalyse mit interaktivem Dashboard
Aktuelle Nachrichten, Updates und Trendanalyse
Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung

Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL ATAXIA MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

4.3 EPIDEMIOLOGY

5 PIPELINE ANALYSIS

6 GLOBAL ATAXIA MARKET: REGULATORY SCENARIO

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE AND INCIDENCES OF ATAXIA

7.1.2 RAPID RESEARCH IN FIELD OF ATAXIA THERAPEUTICS

7.1.3 RISE IN ALCOHOL AND DRUG USAGE

7.1.4 GROWING NUMBER OF INCIDENCES OF AUTO-IMMUNE DISEASE

7.2 RESTRAINTS

7.2.1 DIFFICULTY IN DIAGNOSIS OF DISEASE

7.2.2 LACK OF GENETIC TESTING IN DEVELOPING COUNTRIES

7.3 OPPORTUNITIES

7.3.1 RISING HEALTHCARE EXPENDITURE

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.4 CHALLENGES

7.4.1 STRINGENT RULES AND REGULATIONS

7.4.2 PRODUCT RECALL

8 GLOBAL ATAXIA MARKET, BY TYPE

8.1 OVERVIEW

8.2 SPINOCEREBELLAR ATAXIAS

8.2.1 TYPE 3

8.2.2 TYPE 2

8.2.3 TYPE 1

8.2.4 OTHERS

8.3 ATAXIA-TELANGIECTASIA

8.4 EPISODIC ATAXIA

8.5 OTHERS (MULTIPLE SYSTEM ATROPHY (MSA))

9 GLOBAL ATAXIA MARKET, BY PRODUCT

9.1 OVERVIEW

9.2 TREATMENT

9.2.1 PHARMACOTHERAPY

9.2.1.1 STIFFNESS/SPASTICITY

9.2.1.1.1 GABAPENTIN

9.2.1.1.2 LEVODOPA

9.2.1.1.3 OTHERS

9.2.1.2 GAIT AND TREMORS

9.2.1.2.1 VARENICLINE

9.2.1.2.2 RILUZOLE

9.2.1.2.3 AMANTADINE

9.2.1.2.4 OTHERS

9.2.1.3 ANTI-OXIDANTS

9.2.1.3.1 N‐ACETYLCYSTEINE

9.2.1.3.2 SELEGILINE

9.2.1.3.3 DEHYDROEPIANDROSTERONE

9.2.1.3.4 VITAMIN E

9.2.1.4 NON ANTI-OXIDANTS

9.2.1.4.1 ERYTHROPOIETIN

9.2.1.4.2 DEFERIPRONE

9.2.1.4.3 RESVERATROL

9.2.1.4.4 HISTONE DEACETYLASE INHIBITORS

9.2.1.5 ANTI-ARRHYTHMIC AGENTS

9.2.1.5.1 AMIODARONE

9.2.1.5.2 PROPAFENONE

9.2.1.5.3 FLECAINIDE

9.2.1.5.4 IBUTILIDE

9.2.1.6 ANTI-CARDIAC FAILURE

9.2.1.6.1 BENAZEPRIL

9.2.1.6.2 LISINOPRIL

9.2.1.6.3 CAPTOPRIL

9.2.1.6.4 ENALAPRIL

9.2.1.6.5 FOSINOPRIL

9.2.1.6.6 MOEXIPRIL

9.2.1.6.7 OTHERS

9.2.1.7 ORAL HYPOGLYCEMIC THERAPEUTICS

9.2.1.7.1 BIGUANIDES (METFORMIN)

9.2.1.7.2 SULFONYLUREAS

9.2.1.7.2.1 GLIPIZIDE

9.2.1.7.2.2 GLIMEPIRIDE

9.2.1.7.2.3 GLYBURIDE

9.2.1.7.2.4 OTHERS

9.2.1.7.3 THIAZOLIDINEDIONES

9.2.1.7.4 MEGLITINIDES

9.2.2 LIFESTYLE THERAPY

9.2.2.1 PHYSICAL THERAPY

9.2.2.2 SPEECH THERAPY

9.2.2.3 PALLIATIVE CARE

9.2.2.4 OTHERS

9.2.3 SUPPORTIVE DEVICES

9.2.3.1 WALKING AIDS

9.2.3.2 WHEELCHAIRS

9.2.3.3 OTHERS

9.3 DIAGNOSTICS

9.3.1 IMAGING TEST

9.3.1.1 MRI SCAN

9.3.1.2 OTHERS

9.3.2 BLOOD TEST

9.3.3 GENETIC TESTING

10 GLOBAL ATAXIA MARKET, BY DOSAGE FORM

10.1 OVERVIEW

10.2 SOLID

10.2.1 TABLETS

10.2.2 CAPSULES

10.2.3 OTHERS

10.3 LIQUIDS

10.3.1 INJECTION

10.3.2 SOLUTIONS

10.3.3 OTHERS

10.4 OTHERS

11 GLOBAL ATAXIA MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.3 PARENTERAL

11.4 OTHERS

12 GLOBAL ATAXIA MARKET, BY PATIENT TYPE

12.1 OVERVIEW

12.2 ADULT

12.2.1 MALE

12.2.2 FEMALE

12.3 CHILD

12.4 GERIATRIC

13 GLOBAL ATAXIA MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 CLINICS

13.4 HOME HEALTHCARE

13.5 OTHERS

14 GLOBAL ATAXIA MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDER

14.3 RETAIL SALES

14.3.1 HOSPITAL PHARMACY

14.3.2 RETAIL SHOP

14.3.3 ONLINE PHARMACY

14.4 OTHERS

15 GLOBAL ATAXIA MARKET, BY GEOGRAPHY

15.1 OVERVIEW

15.2 NORTH AMERICA

15.2.1 U.S.

15.2.2 CANADA

15.2.3 MEXICO

15.3 EUROPE

15.3.1 GERMANY

15.3.2 U.K.

15.3.3 FRANCE

15.3.4 ITALY

15.3.5 SPAIN

15.3.6 SWITZERLAND

15.3.7 NETHERLANDS

15.3.8 IRELAND

15.3.9 RUSSIA

15.3.10 HUNGARY

15.3.11 AUSTRIA

15.3.12 NORWAY

15.3.13 POLAND

15.3.14 TURKEY

15.3.15 LITHUANIA

15.3.16 REST OF EUROPE

15.4 ASIA-PACIFIC

15.4.1 CHINA

15.4.2 JAPAN

15.4.3 INDIA

15.4.4 SOUTH KOREA

15.4.5 AUSTRALIA

15.4.6 SINGAPORE

15.4.7 THAILAND

15.4.8 MALAYSIA

15.4.9 INDONESIA

15.4.10 PHILIPPINES

15.4.11 VIETNAM

15.4.12 RESTF OF ASIA-PACIFIC

15.5 SOUTH AMERICA

15.5.1 BRAZIL

15.5.2 ARGENTINA

15.5.3 PERU

15.5.4 RESTF OF SOUTH AMERICA

15.6 MIDDLE EAST AND AFRICA

15.6.1 SOUTH AFRICA

15.6.2 SAUDI ARABIA

15.6.3 U.A.E

15.6.4 ISRAEL

15.6.5 EGYPT

15.6.6 KUWAIT

15.6.7 REST OF MIDDLE EAST AND AFRICA

16 GLOBAL ATAXIA MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: GLOBAL

16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

16.3 COMPANY SHARE ANALYSIS: EUROPE

16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 SELECT MEDICAL CORPORATION

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 PFIZER INC.

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 NOVARTIS AG

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 AMNEAL PHARMACEUTICALS LLC.

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLI

18.4.5 RECENT DEVELOPMENT

18.5 UPSTREAM REHABILITATION INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 COMPANY SHARE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENT

18.6 PRIORY

18.6.1 COMPANY SNAPSHOT

18.6.2 COMPANY SHARE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 ACORDA THERAPEUTICS, INC.

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENTS

18.8 ADVERUM BIOTECHNOLOGIES, INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 APOTEX INC.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENT

18.1 ATI PHYSICAL THERAPY

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 AUROBINDO PHARMA

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.12 BANNER HEALTH

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENT

18.13 BIOHAVEN PHARMACEUTICALS

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENTS

18.14 BIOVISTA

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

18.15 CIPLA INC.

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 DESIGN THERAPEUTICS, INC.

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 INTRABIO

18.17.1 COMPANY SNAPSHOT

18.17.2 PRODUCT PORTFOLIO

18.17.3 RECENT DEVELOPMENT

18.18 LUPIN.

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENTS

18.19 MATRIX BIOMED

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENT

18.2 MERCK KGAA

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENTS

18.21 REATA PHARMACEUTICALS, INC.

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENT

18.22 RETROTOPE INC.

18.22.1 COMPANY SNAPSHOT

18.22.2 PRODUCT PORTFOLIO

18.22.3 RECENT DEVELOPMENT

18.23 SANOFI

18.23.1 COMPANY SNAPSHOT

18.23.2 REVENUE ANALYSIS

18.23.3 PRODUCT PORTFOLIO

18.23.4 RECENT DEVELOPMENT

18.24 SUN PHARMACEUTICAL INDUSTRIES LTD.

18.24.1 COMPANY SNAPSHOT

18.24.2 REVENUE ANALYSIS

18.24.3 PRODUCT PORTFOLIO

18.24.4 RECENT DEVELOPMENT

18.25 SUTTER HEALTH

18.25.1 COMPANY SNAPSHOT

18.25.2 PRODUCT PORTFOLIO

18.25.3 RECENT DEVELOPMENTS

18.26 TEVA PHARMACEUTICAL INDUSTRIES LTD.

18.26.1 COMPANY SNAPSHOT

18.26.2 REVENUE ANALYSIS

18.26.3 PRODUCT PORTFOLIO

18.26.4 RECENT DEVELOPMENT

18.27 VIATRIS INC.

18.27.1 COMPANY SNAPSHOT

18.27.2 REVENUE ANALYSIS

18.27.3 PRODUCT PORTFOLIO

18.27.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

Tabellenverzeichnis

TABLE 1 GLOBAL ATAXIA MARKET: PIPELINE ANALYSIS

TABLE 2 GLOBAL ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 3 GLOBAL SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4 GLOBAL SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 5 GLOBAL ATAXIA-TELANGIECTASIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 6 GLOBAL EPISODIC ATAXIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 7 GLOBAL OTHERS (MULTIPLE SYSTEM ATROPHY (MSA)) IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 8 GLOBAL ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 9 GLOBAL TREATMENT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 10 GLOBAL TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 11 GLOBAL PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 12 GLOBAL STIFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 13 GLOBAL GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 14 GLOBAL ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 15 GLOBAL NON ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 16 GLOBAL ANTI- ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 17 GLOBAL ANTI- CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 18 GLOBAL ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 19 GLOBAL SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 20 GLOBAL LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 21 GLOBAL SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 22 GLOBAL DIAGNOSTICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23 GLOBAL DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 24 GLOBAL IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 25 GLOBAL ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 26 GLOBAL SOLID IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 27 GLOBAL SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 28 GLOBAL LIQUIDS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 29 GLOBAL LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 30 GLOBAL OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31 GLOBAL ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 32 GLOBAL ORAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 33 GLOBAL PARENTERAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 34 GLOBAL OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35 GLOBAL ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 36 GLOBAL ADULT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37 GLOBAL ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 38 GLOBAL CHILD IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 39 GLOBAL GERIATRIC IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40 GLOBAL ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 41 GLOBAL HOSPITAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 42 GLOBAL CLINICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 43 GLOBAL HOME HEALTHCARE IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 44 GLOBAL OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 45 GLOBAL ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 46 GLOBAL DIRECT TENDER IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 47 GLOBAL RETAIL SALES IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 48 GLOBAL RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 49 GLOBAL OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 50 GLOBAL ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 51 NORTH AMERICA ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 52 NORTH AMERICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 53 NORTH AMERICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 54 NORTH AMERICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 55 NORTH AMERICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 56 NORTH AMERICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 57 NORTH AMERICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 58 NORTH AMERICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 59 NORTH AMERICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 60 NORTH AMERICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 61 NORTH AMERICA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 62 NORTH ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 63 NORTH AMERICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 64 NORTH AMERICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 65 NORTH AMERICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 66 NORTH AMERICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 67 NORTH AMERICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 68 NORTH AMERICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 69 NORTH AMERICA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 70 NORTH AMERICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 71 NORTH AMERICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 72 NORTH AMERICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 73 NORTH AMERICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 74 NORTH AMERICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 75 NORTH AMERICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 76 NORTH AMERICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 77 NORTH AMERICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 78 U.S. ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 79 U.S. SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 80 U.S. ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 81 U.S. TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 82 U.S. PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 83 U.S. STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 84 U.S. GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 85 U.S. ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 86 U.S. NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 87 U.S. ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 88 U.S. ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 89 U.S. ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 90 U.S. SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 91 U.S. LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 92 U.S. SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 93 U.S. DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 94 U.S. IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 95 U.S. IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 96 U.S. SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 97 U.S. LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 98 U.S. ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 99 U.S. ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 100 U.S. ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 101 U.S. ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 102 U.S. ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 103 U.S. RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 104 CANADA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 105 CANADA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 106 CANADA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 107 CANADA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 108 CANADA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 109 CANADA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 110 CANADA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 111 CANADA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 112 CANADA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 113 CANADA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 114 CANADA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 115 CANADA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 116 CANADA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 117 CANADA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 118 CANADA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 119 CANADA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 120 CANADA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 121 CANADA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 122 CANADA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 123 CANADA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 124 CANADA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 125 CANADA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 126 CANADA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 127 CANADA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 128 CANADA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 129 CANADA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 130 MEXICO ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 131 MEXICO SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 132 MEXICO ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 133 MEXICO TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 134 MEXICO PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 135 MEXICO STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 136 MEXICO GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 137 MEXICO ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 138 MEXICO NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 139 MEXICO ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 140 MEXICO ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 141 MEXICO ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 142 MEXICO SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 143 MEXICO LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 144 MEXICO SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 145 MEXICO DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 146 MEXICO IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 147 \MEXICO IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 148 MEXICO SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 149 MEXICO LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 150 MEXICO ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 151 MEXICO ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 152 MEXICO ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 153 MEXICO ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 154 MEXICO ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 155 MEXICO RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 156 EUROPE ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 157 EUROPE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 158 EUROPE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 159 EUROPE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 160 EUROPE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 161 EUROPE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 162 EUROPE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 163 EUROPE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 164 EUROPE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 165 EUROPE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 166 EUROPE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 167 EUROPE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 168 EUROPE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 169 EUROPE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 170 EUROPE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 171 EUROPE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 172 EUROPE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 173 EUROPE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 174 EUROPE ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 175 EUROPE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 176 EUROPE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 177 EUROPE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 178 EUROPE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 179 EUROPE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 180 EUROPE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 181 EUROPE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 182 EUROPE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 183 GERMANY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 184 GERMANY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 185 GERMANY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 186 GERMANY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 187 GERMANY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 188 GERMANY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 189 GERMANY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 190 GERMANY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 191 GERMANY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 192 GERMANY ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 193 GERMANY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 194 GERMANY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 195 GERMANY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 196 GERMANY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 197 GERMANY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 198 GERMANY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 199 GERMANY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 200 GERMANY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 201 GERMANY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 202 GERMANY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 203 GERMANY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 204 GERMANY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 205 GERMANY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 206 GERMANY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 207 GERMANY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 208 GERMANY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 209 U.K. ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 210 U.K. SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 211 U.K. ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 212 U.K. TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 213 U.K. PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 214 U.K. STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 215 U.K. GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 216 U.K. ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 217 U.K. NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 218 U.K. ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 219 U.K. ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 220 U.K. ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 221 U.K. SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 222 U.K. LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 223 U.K. SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 224 U.K. DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 225 U.K. IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 226 U.K. ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 227 U.K. SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 228 U.K. LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 229 U.K. ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 230 U.K. ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 231 U.K. ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 232 U.K. ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 233 U.K. ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 234 U.K. RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 235 FRANCE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 236 FRANCE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 237 FRANCE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 238 FRANCE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 239 FRANCE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 240 FRANCE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 241 FRANCE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 242 FRANCE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 243 FRANCE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 244 FRANCE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 245 FRANCE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 246 FRANCE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 247 FRANCE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 248 FRANCE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 249 FRANCE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 250 FRANCE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 251 FRANCE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 252 FRANCE ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 253 FRANCE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 254 FRANCE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 255 FRANCE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 256 FRANCE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 257 FRANCE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 258 FRANCE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 259 FRANCE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 260 FRANCE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 261 ITALY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 262 ITALY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 263 ITALY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 264 ITALY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 265 ITALY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 266 ITALY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 267 ITALY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 268 ITALY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 269 ITALY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 270 ITALY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 271 ITALY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 272 ITALY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 273 ITALY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 274 ITALY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 275 ITALY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 276 ITALY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 277 ITALY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 278 ITALY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 279 ITALY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 280 ITALY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 281 ITALY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 282 ITALY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 283 ITALY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 284 ITALY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 285 ITALY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 286 ITALY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 287 SPAIN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 288 SPAIN SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 289 SPAIN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 290 SPAIN TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 291 SPAIN PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 292 SPAIN STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 293 SPAIN GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 294 SPAIN ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 295 SPAIN NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 296 SPAIN ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 297 SPAIN ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 298 SPAIN ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 299 SPAIN SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 300 SPAIN LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 301 SPAIN SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 302 SPAIN DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 303 SPAIN IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 304 SPAIN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 305 SPAIN SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 306 SPAIN LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 307 SPAIN ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 308 SPAIN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 309 SPAIN ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 310 SPAIN ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 311 SPAIN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 312 SPAIN RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 313 SWITZERLAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 314 SWITZERLAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 315 SWITZERLAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 316 SWITZERLAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 317 SWITZERLAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 318 SWITZERLAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 319 SWITZERLAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 320 SWITZERLAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 321 SWITZERLAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 322 SWITZERLAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 323 SWITZERLAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 324 SWITZERLAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 325 SWITZERLAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 326 SWITZERLAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 327 SWITZERLAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 328 SWITZERLAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 329 SWITZERLAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 330 SWITZERLAND ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 331 SWITZERLAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 332 SWITZERLAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 333 SWITZERLAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 334 SWITZERLAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 335 SWITZERLAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 336 SWITZERLAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 337 SWITZERLAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 338 SWITZERLAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 339 NETHERLANDS ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 340 NETHERLANDS SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 341 NETHERLANDS ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 342 NETHERLANDS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 343 NETHERLANDS PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 344 NETHERLANDS STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 345 NETHERLANDS GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 346 NETHERLANDS ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 347 NETHERLANDS NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 348 NETHERLANDS ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 349 NETHERLANDS ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 350 NETHERLANDS ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 351 NETHERLANDS SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 352 NETHERLANDS LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 353 NETHERLANDS SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 354 NETHERLANDS DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 355 NETHERLANDS IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 356 NETHERLANDS ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 357 NETHERLANDS SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 358 NETHERLANDS LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 359 NETHERLANDS ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 360 NETHERLANDS ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 361 NETHERLANDS ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 362 NETHERLANDS ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 363 NETHERLANDS ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 364 NETHERLANDS RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 365 IRELAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 366 IRELAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 367 IRELAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 368 IRELAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 369 IRELAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 370 IRELAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 371 IRELAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 372 IRELAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 373 IRELAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 374 IRELAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 375 IRELAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 376 IRELAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 377 IRELAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 378 IRELAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 379 IRELAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 380 IRELAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 381 IRELAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 382 IRELAND ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 383 IRELAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 384 IRELAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 385 IRELAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 386 IRELAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 387 IRELAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 388 IRELAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 389 IRELAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 390 IRELAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 391 RUSSIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 392 RUSSIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 393 RUSSIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 394 RUSSIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 395 RUSSIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 396 RUSSIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 397 RUSSIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 398 RUSSIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 399 RUSSIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 400 RUSSIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 401 RUSSIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 402 RUSSIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 403 RUSSIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 404 RUSSIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 405 RUSSIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 406 RUSSIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 407 RUSSIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 408 RUSSIA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 409 RUSSIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 410 RUSSIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 411 RUSSIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 412 RUSSIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 413 RUSSIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 414 RUSSIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 415 RUSSIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 416 RUSSIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 417 HUNGARY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 418 HUNGARY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 419 HUNGARY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 420 HUNGARY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 421 HUNGARY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 422 HUNGARY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 423 HUNGARY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 424 HUNGARY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 425 HUNGARY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 426 HUNGARY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 427 HUNGARY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 428 HUNGARY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 429 HUNGARY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 430 HUNGARY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 431 HUNGARY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 432 HUNGARY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 433 HUNGARY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 434 HUNGARY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 435 HUNGARY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 436 HUNGARY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 437 HUNGARY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 438 HUNGARY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 439 HUNGARY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 440 HUNGARY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 441 HUNGARY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 442 HUNGARY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 443 AUSTRIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 444 AUSTRIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 445 AUSTRIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 446 AUSTRIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 447 AUSTRIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 448 AUSTRIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 449 AUSTRIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 450 AUSTRIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 451 AUSTRIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 452 AUSTRIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 453 AUSTRIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 454 AUSTRIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 455 AUSTRIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 456 AUSTRIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 457 AUSTRIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 458 AUSTRIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 459 AUSTRIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 460 AUSTRIA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 461 AUSTRIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 462 AUSTRIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 463 AUSTRIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 464 AUSTRIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 465 AUSTRIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 466 AUSTRIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 467 AUSTRIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 468 AUSTRIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 469 NORWAY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 470 NORWAY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 471 NORWAY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 472 NORWAY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 473 NORWAY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 474 NORWAY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 475 NORWAY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 476 NORWAY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 477 NORWAY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 478 NORWAY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 479 NORWAY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 480 NORWAY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 481 NORWAY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 482 NORWAY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 483 NORWAY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 484 NORWAY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 485 NORWAY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 486 NORWAY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 487 NORWAY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 488 NORWAY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 489 NORWAY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 490 NORWAY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 491 NORWAY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 492 NORWAY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 493 NORWAY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 494 NORWAY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 495 POLAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 496 POLAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 497 POLAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 498 POLAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 499 POLAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 500 POLAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 501 POLAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 502 POLAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 503 POLAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 504 POLAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 505 POLAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 506 POLAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 507 POLAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 508 POLAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 509 POLAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 510 POLAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 511 POLAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 512 POLAND ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 513 POLAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 514 POLAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 515 POLAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 516 POLAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 517 POLAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 518 POLAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 519 POLAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 520 POLAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 521 TURKEY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 522 TURKEY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 523 TURKEY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 524 TURKEY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 525 TURKEY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 526 TURKEY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 527 TURKEY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 528 TURKEY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 529 TURKEY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 530 TURKEY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 531 TURKEY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 532 TURKEY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 533 TURKEY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 534 TURKEY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 535 TURKEY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 536 TURKEY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 537 TURKEY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 538 TURKEY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 539 TURKEY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 540 TURKEY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 541 TURKEY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 542 TURKEY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 543 TURKEY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 544 TURKEY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 545 TURKEY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 546 TURKEY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 547 LITHUANIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 548 LITHUANIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 549 LITHUANIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 550 LITHUANIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 551 LITHUANIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 552 LITHUANIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 553 LITHUANIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 554 LITHUANIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 555 LITHUANIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 556 LITHUANIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 557 LITHUANIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 558 LITHUANIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 559 LITHUANIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 560 LITHUANIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 561 LITHUANIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 562 LITHUANIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 563 LITHUANIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 564 LITHUANIA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 565 LITHUANIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 566 LITHUANIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 567 LITHUANIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 568 LITHUANIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 569 LITHUANIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 570 LITHUANIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 571 LITHUANIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 572 LITHUANIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 573 REST OF EUROPE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 574 ASIA-PACIFIC ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 575 ASIA-PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 576 ASIA-PACIFIC SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 577 ASIA-PACIFIC ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 578 ASIA-PACIFIC TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 579 ASIA-PACIFIC PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 580 ASIA-PACIFIC STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 581 ASIA-PACIFIC GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 582 ASIA-PACIFIC ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 583 ASIA-PACIFIC NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 584 ASIA-PACIFIC ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 585 ASIA-PACIFIC ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 586 ASIA-PACIFIC ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 587 ASIA-PACIFIC SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 588 ASIA-PACIFIC LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 589 ASIA-PACIFIC SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 590 ASIA-PACIFIC DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 591 ASIA-PACIFIC IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 592 ASIA-PACIFIC IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 593 ASIA-PACIFIC SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 594 ASIA-PACIFIC LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 595 ASIA-PACIFIC ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 596 ASIA-PACIFIC ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 597 ASIA-PACIFIC ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 598 ASIA-PACIFIC ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 599 ASIA-PACIFIC ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 600 ASIA-PACIFIC RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 601 CHINA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 602 CHINA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 603 CHINA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 604 CHINA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 605 CHINA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 606 CHINA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 607 CHINA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 608 CHINA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 609 CHINA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 610 CHINA ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 611 CHINA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 612 CHINA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 613 CHINA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 614 CHINA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 615 CHINA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 616 CHINA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 617 CHINA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 618 CHINA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 619 CHINA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 620 CHINA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 621 CHINA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 622 CHINA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 623 CHINA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 624 CHINA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 625 CHINA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 626 CHINA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 627 JAPAN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 628 JAPAN SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 629 JAPAN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 630 JAPAN TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 631 JAPAN PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 632 JAPAN STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 633 JAPAN GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 634 JAPAN ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 635 JAPAN NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 636 JAPAN ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 637 JAPAN ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 638 JAPAN ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 639 JAPAN SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 640 JAPAN LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 641 JAPAN SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 642 JAPAN DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 643 JAPAN IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 644 JAPAN IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 645 JAPAN SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 646 JAPAN LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 647 JAPAN ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 648 JAPAN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 649 JAPAN ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 650 JAPAN ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 651 JAPAN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 652 JAPAN RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 653 INDIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 654 INDIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 655 INDIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 656 INDIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 657 INDIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 658 INDIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 659 INDIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 660 INDIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 661 INDIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 662 INDIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 663 INDIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 664 INDIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 665 INDIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 666 INDIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 667 INDIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 668 INDIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 669 INDIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 670 INDIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 671 INDIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 672 INDIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 673 INDIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 674 INDIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 675 INDIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 676 INDIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 677 INDIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 678 INDIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 679 SOUTH KOREA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 680 SOUTH KOREA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 681 SOUTH KOREA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 682 SOUTH KOREA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 683 SOUTH KOREA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 684 SOUTH KOREA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 685 SOUTH KOREA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 686 SOUTH KOREA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 687 SOUTH KOREA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 688 SOUTH KOREA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 689 SOUTH KOREA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 690 SOUTH KOREA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 691 SOUTH KOREA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 692 SOUTH KOREA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 693 SOUTH KOREA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 694 SOUTH KOREA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 695 SOUTH KOREA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 696 SOUTH KOREA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 697 SOUTH KOREA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 698 SOUTH KOREA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 699 SOUTH KOREA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 700 SOUTH KOREA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 701 SOUTH KOREA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 702 SOUTH KOREA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 703 SOUTH KOREA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 704 SOUTH KOREA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 705 AUSTRALIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 706 AUSTRALIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 707 AUSTRALIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 708 AUSTRALIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 709 AUSTRALIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 710 AUSTRALIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 711 AUSTRALIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 712 AUSTRALIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 713 AUSTRALIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 714 AUSTRALIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 715 AUSTRALIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 716 AUSTRALIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 717 AUSTRALIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 718 AUSTRALIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 719 AUSTRALIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 720 AUSTRALIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 721 AUSTRALIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 722 AUSTRALIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 723 AUSTRALIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 724 AUSTRALIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 725 AUSTRALIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 726 AUSTRALIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 727 AUSTRALIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 728 AUSTRALIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 729 AUSTRALIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 730 AUSTRALIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 731 SINGAPORE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 732 SINGAPORE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 733 SINGAPORE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 734 SINGAPORE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 735 SINGAPORE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 736 SINGAPORE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 737 SINGAPORE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 738 SINGAPORE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 739 SINGAPORE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 740 SINGAPORE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 741 SINGAPORE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 742 SINGAPORE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 743 SINGAPORE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 744 SINGAPORE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 745 SINGAPORE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 746 SINGAPORE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 747 SINGAPORE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 748 SINGAPORE IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 749 SINGAPORE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 750 SINGAPORE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 751 SINGAPORE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 752 SINGAPORE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 753 SINGAPORE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 754 SINGAPORE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 755 SINGAPORE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 756 SINGAPORE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 757 THAILAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 758 THAILAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 759 THAILAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 760 THAILAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 761 THAILAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 762 THAILAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 763 THAILAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 764 THAILAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 765 THAILAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 766 THAILAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 767 THAILAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 768 THAILAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 769 THAILAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 770 THAILAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 771 THAILAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 772 THAILAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 773 THAILAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 774 THAILAND IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 775 THAILAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 776 THAILAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 777 THAILAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 778 THAILAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 779 THAILAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 780 THAILAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 781 THAILAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 782 THAILAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 783 MALAYSIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 784 MALAYSIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 785 MALAYSIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 786 MALAYSIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 787 MALAYSIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 788 MALAYSIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 789 MALAYSIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 790 MALAYSIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 791 MALAYSIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 792 MALAYSIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 793 MALAYSIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 794 MALAYSIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 795 MALAYSIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 796 MALAYSIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 797 MALAYSIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 798 MALAYSIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 799 MALAYSIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 800 MALAYSIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 801 MALAYSIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 802 MALAYSIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 803 MALAYSIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 804 MALAYSIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 805 MALAYSIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 806 MALAYSIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 807 MALAYSIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 808 MALAYSIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 809 INDONESIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 810 INDONESIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 811 INDONESIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 812 INDONESIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 813 INDONESIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 814 INDONESIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 815 INDONESIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 816 INDONESIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 817 INDONESIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 818 INDONESIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 819 INDONESIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 820 INDONESIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 821 INDONESIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 822 INDONESIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 823 INDONESIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 824 INDONESIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 825 INDONESIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 826 INDONESIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 827 INDONESIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 828 INDONESIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 829 INDONESIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 830 INDONESIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 831 INDONESIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 832 INDONESIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 833 INDONESIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 834 INDONESIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 835 PHILIPPINES ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 836 PHILIPPINES SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 837 PHILIPPINES ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 838 PHILIPPINES TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 839 PHILIPPINES PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 840 PHILIPPINES STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 841 PHILIPPINES GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 842 PHILIPPINES ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 843 PHILIPPINES NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 844 PHILIPPINES ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 845 PHILIPPINES ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 846 PHILIPPINES ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 847 PHILIPPINES SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 848 PHILIPPINES LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 849 PHILIPPINES SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 850 PHILIPPINES DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 851 PHILIPPINES IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 852 PHILIPPINES IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 853 PHILIPPINES SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 854 PHILIPPINES LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 855 PHILIPPINES ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 856 PHILIPPINES ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 857 PHILIPPINES ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 858 PHILIPPINES ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 859 PHILIPPINES ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 860 PHILIPPINES RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 861 VIETNAM ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 862 VIETNAM SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 863 VIETNAM ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 864 VIETNAM TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 865 VIETNAM PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 866 VIETNAM STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 867 VIETNAM GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 868 VIETNAM ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 869 VIETNAM NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 870 VIETNAM ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 871 VIETNAM ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 872 VIETNAM ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 873 VIETNAM SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 874 VIETNAM LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 875 VIETNAM SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 876 VIETNAM DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 877 VIETNAM IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 878 VIETNAM IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 879 VIETNAM SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 880 VIETNAM LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 881 VIETNAM ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 882 VIETNAM ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 883 VIETNAM ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 884 VIETNAM ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 885 VIETNAM ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 886 VIETNAM RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 887 RESTF OF ASIA-PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 888 SOUTH AMERICA ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 889 SOUTH AMERICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 890 SOUTH AMERICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 891 SOUTH AMERICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 892 SOUTH AMERICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 893 SOUTH AMERICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 894 SOUTH AMERICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 895 SOUTH AMERICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 896 SOUTH AMERICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 897 SOUTH AMERICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 898 SOUTH AMERICA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 899 SOUTH AMERICA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 900 SOUTH AMERICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 901 SOUTH AMERICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 902 SOUTH AMERICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 903 SOUTH AMERICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 904 SOUTH AMERICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 905 SOUTH AMERICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 906 SOUTH AMERICA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 907 SOUTH AMERICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 908 SOUTH AMERICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 909 SOUTH AMERICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 910 SOUTH AMERICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 911 SOUTH AMERICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 912 SOUTH AMERICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 913 SOUTH AMERICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 914 SOUTH AMERICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 915 BRAZIL ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 916 BRAZIL SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 917 BRAZIL ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 918 BRAZIL TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 919 BRAZIL PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 920 BRAZIL STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 921 BRAZIL GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 922 BRAZIL ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 923 BRAZIL NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 924 BRAZIL ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 925 BRAZIL ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 926 BRAZIL ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 927 BRAZIL SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 928 BRAZIL LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 929 BRAZIL SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 930 BRAZIL DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 931 BRAZIL IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 932 BRAZIL IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 933 BRAZIL SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 934 BRAZIL LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 935 BRAZIL ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 936 BRAZIL ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 937 BRAZIL ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 938 BRAZIL ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 939 BRAZIL ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 940 BRAZIL RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 941 ARGENTINA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 942 ARGENTINA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 943 ARGENTINA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 944 ARGENTINA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 945 ARGENTINA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 946 ARGENTINA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 947 ARGENTINA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 948 ARGENTINA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 949 ARGENTINA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 950 ARGENTINA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 951 ARGENTINA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 952 ARGENTINA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 953 ARGENTINA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 954 ARGENTINA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 955 ARGENTINA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 956 ARGENTINA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 957 ARGENTINA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 958 ARGENTINA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 959 ARGENTINA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 960 ARGENTINA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 961 ARGENTINA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 962 ARGENTINA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 963 ARGENTINA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 964 ARGENTINA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 965 ARGENTINA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 966 ARGENTINA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 967 PERU ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 968 PERU SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 969 PERU ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 970 PERU TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 971 PERU PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 972 PERU STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 973 PERU GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 974 PERU ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 975 PERU NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 976 PERU ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 977 PERU ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 978 PERU ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 979 PERU SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 980 PERU LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 981 PERU SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 982 PERU DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 983 PERU IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 984 PERU IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 985 PERU SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 986 PERU LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 987 PERU ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 988 PERU ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 989 PERU ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 990 PERU ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 991 PERU ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 992 PERU RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 993 RESTF OF SOUTH AMERICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 994 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 995 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 996 MIDDLE EAST AND AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 997 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 998 MIDDLE EAST AND AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 999 MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1000 MIDDLE EAST AND AFRICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1001 MIDDLE EAST AND AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1002 MIDDLE EAST AND AFRICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1003 MIDDLE EAST AND AFRICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1004 MIDDLE EAST AND AFRICA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1005 MIDDLE EAST AND AFRICA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1006 MIDDLE EAST AND AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1007 MIDDLE EAST AND AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1008 MIDDLE EAST AND AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1009 MIDDLE EAST AND AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1010 MIDDLE EAST AND AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1011 MIDDLE EAST AND AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1012 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1013 MIDDLE EAST AND AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1014 MIDDLE EAST AND AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1015 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1016 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1017 MIDDLE EAST AND AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1018 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1019 MIDDLE EAST AND AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1020 MIDDLE EAST AND AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1021 SOUTH AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1022 SOUTH AFRICA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1023 SOUTH AFRICA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1024 SOUTH AFRICA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1025 SOUTH AFRICA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1026 SOUTH AFRICA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1027 SOUTH AFRICA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1028 SOUTH AFRICA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1029 SOUTH AFRICA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1030 SOUTH AFRICA ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1031 SOUTH AFRICA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1032 SOUTH AFRICA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1033 SOUTH AFRICA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1034 SOUTH AFRICA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1035 SOUTH AFRICA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1036 SOUTH AFRICA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1037 SOUTH AFRICA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1038 SOUTH AFRICA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1039 SOUTH AFRICA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1040 SOUTH AFRICA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1041 SOUTH AFRICA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1042 SOUTH AFRICA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1043 SOUTH AFRICA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1044 SOUTH AFRICA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1045 SOUTH AFRICA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1046 SOUTH AFRICA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1047 SAUDI ARABIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1048 SAUDI ARABIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1049 SAUDI ARABIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1050 SAUDI ARABIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1051 SAUDI ARABIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1052 SAUDI ARABIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1053 SAUDI ARABIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1054 SAUDI ARABIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1055 SAUDI ARABIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1056 SAUDI ARABIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1057 SAUDI ARABIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1058 SAUDI ARABIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1059 SAUDI ARABIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1060 SAUDI ARABIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1061 SAUDI ARABIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1062 SAUDI ARABIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1063 SAUDI ARABIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1064 SAUDI ARABIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1065 SAUDI ARABIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1066 SAUDI ARABIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1067 SAUDI ARABIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1068 SAUDI ARABIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1069 SAUDI ARABIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1070 SAUDI ARABIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1071 SAUDI ARABIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1072 SAUDI ARABIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1073 U.A.E ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1074 U.A.E SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1075 U.A.E ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1076 U.A.E TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1077 U.A.E PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1078 U.A.E STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1079 U.A.E GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1080 U.A.E ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1081 U.A.E NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1082 U.A.E ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1083 U.A.E ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1084 U.A.E ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1085 U.A.E SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1086 U.A.E LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1087 U.A.E SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1088 U.A.E DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1089 U.A.E IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1090 U.A.E IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1091 U.A.E SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1092 U.A.E LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1093 U.A.E ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1094 U.A.E ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1095 U.A.E ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1096 U.A.E ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1097 U.A.E ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1098 U.A.E RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1099 ISRAEL ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1100 ISRAEL SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1101 ISRAEL ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1102 ISRAEL TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1103 ISRAEL PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1104 ISRAEL STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1105 ISRAEL GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1106 ISRAEL ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1107 ISRAEL NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1108 ISRAEL ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1109 ISRAEL ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1110 ISRAEL ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1111 ISRAEL SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1112 ISRAEL LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1113 ISRAEL SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1114 ISRAEL DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1115 ISRAEL IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1116 ISRAEL IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1117 ISRAEL SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1118 ISRAEL LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1119 ISRAEL ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1120 ISRAEL ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1121 ISRAEL ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1122 ISRAEL ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1123 ISRAEL ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1124 ISRAEL RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1125 EGYPT ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1126 EGYPT SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1127 EGYPT ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1128 EGYPT TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1129 EGYPT PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1130 EGYPT STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1131 EGYPT GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1132 EGYPT ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1133 EGYPT NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1134 EGYPT ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1135 EGYPT ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1136 EGYPT ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1137 EGYPT SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1138 EGYPT LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1139 EGYPT SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1140 EGYPT DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1141 EGYPT IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1142 EGYPT IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1143 EGYPT SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1144 EGYPT LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1145 EGYPT ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1146 EGYPT ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1147 EGYPT ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1148 EGYPT ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1149 EGYPT ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1150 EGYPT RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1151 KUWAIT ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1152 KUWAIT SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 1153 KUWAIT ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1154 KUWAIT TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1155 KUWAIT PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1156 KUWAIT STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1157 KUWAIT GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1158 KUWAIT ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1159 KUWAIT NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1160 KUWAIT ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1161 KUWAIT ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1162 KUWAIT ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1163 KUWAIT SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1164 KUWAIT LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1165 KUWAIT SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1166 KUWAIT DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1167 KUWAIT IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 1168 KUWAIT IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1169 KUWAIT SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1170 KUWAIT LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 1171 KUWAIT ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 1172 KUWAIT ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1173 KUWAIT ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 1174 KUWAIT ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 1175 KUWAIT ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1176 KUWAIT RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 1177 REST OF MIDDLE EAST AND AFRICA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

Abbildungsverzeichnis

FIGURE 1 GLOBAL ATAXIA MARKET: SEGMENTATION

FIGURE 2 GLOBAL ATAXIA MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL ATAXIA MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL ATAXIA MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL ATAXIA MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL ATAXIA MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL ATAXIA MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL ATAXIA MARKET: END USER COVERAGE GRID

FIGURE 9 GLOBAL ATAXIA MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL ATAXIA MARKET: SEGMENTATION

FIGURE 11 RAPID RESEARCH IN FIELD OF ATAXIA THEREPEUTICS IS EXPECTED TO DRIVE THE GLOBAL ATAXIA MARKET IN THE FORECAST PERIOD

FIGURE 12 SPINOCEREBELLAR ATAXIAS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ATAXIA MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL ATAXIA MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL ATAXIA MARKET MANUFACTURERS IN THE FORECAST PERIOD

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL ATAXIA MARKET

FIGURE 16 GLOBAL ATAXIA MARKET: BY TYPE, 2021

FIGURE 17 GLOBAL ATAXIA MARKET: BY TYPE, 2022-2029 (USD THOUSAND)

FIGURE 18 GLOBAL ATAXIA MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 19 GLOBAL ATAXIA MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 GLOBAL ATAXIA MARKET: BY PRODUCT, 2021

FIGURE 21 GLOBAL ATAXIA MARKET: BY PRODUCT, 2022-2029 (USD THOUSAND)

FIGURE 22 GLOBAL ATAXIA MARKET: BY PRODUCT, CAGR (2022-2029)

FIGURE 23 GLOBAL ATAXIA MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 24 GLOBAL ATAXIA MARKET: BY DOSAGE FORM, 2021

FIGURE 25 GLOBAL ATAXIA MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)

FIGURE 26 GLOBAL ATAXIA MARKET: BY DOSAGE FORM, CAGR (2022-2029)

FIGURE 27 GLOBAL ATAXIA MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 28 GLOBAL ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 29 GLOBAL ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD THOUSAND)

FIGURE 30 GLOBAL ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 31 GLOBAL ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 32 GLOBAL ATAXIA MARKET: BY PATIENT TYPE, 2021

FIGURE 33 GLOBAL ATAXIA MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)

FIGURE 34 GLOBAL ATAXIA MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 35 GLOBAL ATAXIA MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 36 GLOBAL ATAXIA MARKET: BY END USER, 2021

FIGURE 37 GLOBAL ATAXIA MARKET: BY END USER, 2022-2029 (USD THOUSAND)

FIGURE 38 GLOBAL ATAXIA MARKET: BY END USER, CAGR (2022-2029)

FIGURE 39 GLOBAL ATAXIA MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 GLOBAL ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 41 GLOBAL ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)

FIGURE 42 GLOBAL ATAXIA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 43 GLOBAL ATAXIA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 GLOBAL ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 45 GLOBAL ATAXIA MARKET: BY REGION (2021)

FIGURE 46 GLOBAL ATAXIA MARKET: BY REGION (2022 & 2029)

FIGURE 47 GLOBAL ATAXIA MARKET: BY REGION (2021 & 2029)

FIGURE 48 GLOBAL ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 49 NORTH AMERICA ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 50 NORTH AMERICA ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 51 NORTH AMERICA ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 52 NORTH AMERICA ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 53 NORTH AMERICA ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 54 EUROPE ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 55 EUROPE ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 56 EUROPE ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 57 EUROPE ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 58 EUROPE ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 59 ASIA-PACIFIC ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 60 ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 61 ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 62 ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 63 ASIA-PACIFIC ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 64 SOUTH AMERICA ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 65 SOUTH AMERICA ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 66 SOUTH AMERICA ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 67 SOUTH AMERICA ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 68 SOUTH AMERICA ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 69 MIDDLE EAST AND AFRICA ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 70 MIDDLE EAST AND AFRICA ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 71 MIDDLE EAST AND AFRICA ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 72 MIDDLE EAST AND AFRICA ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 73 MIDDLE EAST AND AFRICA ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 74 GLOBAL ATAXIA MARKET: COMPANY SHARE 2021 (%)

FIGURE 75 NORTH AMERICA ATAXIA MARKET: COMPANY SHARE 2021 (%)

FIGURE 76 EUROPE ATAXIA MARKET: COMPANY SHARE 2021 (%)

FIGURE 77 ASIA-PACIFIC ATAXIA MARKET: COMPANY SHARE 2021 (%)

Detaillierte Informationen anzeigen

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

What are the primary segments covered in the Global Ataxia Market report?

The market is segmented based on , By Type (Spinocerebellar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), Product (Treatment and Diagnosis), Dosage Form (Solid, Liquids, and Others), Route of Administration (Oral, Parenteral, and Others), Patient Type (Adult, Child, and Geriatric), End User (Hospital, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2029. .

What is the current market size of the Global Ataxia Market?

The Global Ataxia Market size was valued at USD 22631.81 USD Thousand in 2021.

What is the expected growth rate of the Global Ataxia Market?

The Global Ataxia Market is projected to grow at a CAGR of 6.9% during the forecast period of 2022 to 2029.

Who are the key players in the Global Ataxia Market?

The major players operating in the market include Novartis, Merck, Aurobindo Pharma, Pfizer, Sanofi, Teva Pharmaceutical Industries, Acorda Therapeutics, Viatris, Sun Pharmaceutical Industries, Lupin, Amneal Pharmaceuticals, Apotex, Cipla, Biovista, Design Therapeutics, Reata Pharmaceuticals, MATRIX BIOMED, Intrabio, Biohaven Pharmaceuticals, Retrotope, Adverum Biotechnologies, Priory, Sutter Health, Upstream Rehabilitation, Banner Health, Select Medical Corporation, ATI Physical Therapy.

Which countries are analyzed in the Global Ataxia Market report?

The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Switzerland, Ireland, Russia, Hungary, Austria, Norway, Poland, Turkey, Lithuania, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait, Rest of the Middle East and Africa.

Globaler Ataxiemarkt – Branchentrends und Prognose bis 2029

Globaler Ataxiemarkt – Branchentrends und Prognose bis 2029

Global Ataxia Market

CAGR : 6.90 %

Globale Ataxie-Marktanalyse und Einblicke

Globale Ataxie-Marktdynamik

Auswirkungen von COVID-19 auf den globalen Ataxiemarkt

Globaler Ataxie-Marktumfang

Globaler Ataxie-Markt – Regionale Analyse/Einblicke

Wettbewerbsumfeld und globale Ataxie- Marktanteilsanalyse

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Berichte

Markteinblicke

Unterstützung

Lösungen

Globaler Ataxiemarkt – Branchentrends und Prognose bis 2029

Globaler Ataxiemarkt – Branchentrends und Prognose bis 2029

Global Ataxia Market

CAGR : 6.90 %

Globale Ataxie-Marktanalyse und Einblicke

Globale Ataxie-Marktdynamik

Auswirkungen von COVID-19 auf den globalen Ataxiemarkt

Globaler Ataxie-Marktumfang

Globaler Ataxie-Markt – Regionale Analyse/Einblicke

Wettbewerbsumfeld und globale Ataxie- Marktanteilsanalyse

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Verwandte Seiten durchsuchen